This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study


Likitjaroen, Y., Meindl, T., Friese, U., Wagner, M., Buerger, K., Hampel, H., Teipel, S. J.


European Archives Of Psychiatry And Clinical Neuroscience, Volume: 262, No.: 4, Pages.: 341-350

Year of Publication



Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer’s disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white matter microstructure in AD patients. We enrolled 28 AD patients and 11 healthy elderly control subjects (HC). AD patients were randomly assigned to 6-month double-blind galantamine treatment or placebo, with a 6-month open-label extension phase. DTI was performed at baseline, as well as at 6 and 12-month follow-up in AD patients. The HC subjects underwent DTI at baseline and 12-month follow-up without treatment. We measured FA in regions of interest covering the posterior cingulate and corpus callosum. At 6-month follow-up, the AD group showed significant FA decline in the left posterior cingulate. FA decline was significantly preserved in the posterior body of the corpus callosum in AD group with treatment compared to placebo. At 12-month follow-up, the AD patients showed no differences in FA decline between initial treatment and placebo groups after the 6-month open-label extension phase. A significant FA decline occurred in the left posterior cingulate across the AD and HC groups without between-group differences. DTI demonstrated FA decline in intracortically projecting fiber tracts in aging and AD over 1 year. Galantamine had limited impact on regional FA decline, which was not preserved after additional 6-month open-label treatment.;

Bibtex Citation

@article{Likitjaroen_2011, doi = {10.1007/s00406-011-0234-2}, url = {}, year = 2011, month = {aug}, publisher = {Springer Science $mathplus$ Business Media}, volume = {262}, number = {4}, pages = {341--350}, author = {Y. Likitjaroen and T. Meindl and U. Friese and M. Wagner and K. Buerger and H. Hampel and S. J. Teipel}, title = {Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study}, journal = {Eur Arch Psychiatry Clin Neurosci} }


5x, administration & dosage, aged, aged, 80 and over, alzheimer disease, anisotropy, biological availability, cholinesterase inhibitors, corpus callosum, diagnosis, diffusion tensor imaging, double-blind method, drug effects, drug therapy, female, fractional, galantamine, gyrus cinguli, humans, male, methods, nerve fibers myelinated, neuropsychological tests, out, outcome assessment (health care), pathology, pharmacokinetics, physiopathology

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime